Treatment options for epithelial ovarian cancers are under constant ev
olution. Recent advances have occurred in both first-line and second-l
ine chemotherapeutic regimens. A newly published approach to first-lin
e therapy incorporating intraperitoneal chemotherapy has demonstrated
a benefit in selected patients. There are several new drugs showing ac
tivity in platinum-resistant epithelial ovarian cancer. 1040-872X (C)
1998 Rapid Science Publishers.